(-0.24%) 5 054.75 points
(-0.06%) 37 972 points
(-0.55%) 17 475 points
(-1.09%) $81.04
(-2.76%) $1.936
(-0.22%) $2 297.80
(0.14%) $26.69
(-0.61%) $942.40
(0.17%) $0.939
(0.30%) $11.13
(0.19%) $0.802
(0.17%) $93.61
0.46% ¥ 2 644.00
Live Chart Being Loaded With Signals
CMIC HOLDINGS Co., Ltd. provides various services for the pharmaceutical industry in Japan. The company operates in five segments: Contract Research Organization, Contract Development and Manufacturing Organization, Contract Sales Organization, Healthcare, and Innovative Pharma Model...
Stats | |
---|---|
Dagens volum | 283 600 |
Gjennomsnittsvolum | 40 111.00 |
Markedsverdi | 44.64B |
EPS | ¥0 ( 2024-04-26 ) |
Neste inntjeningsdato | ( ¥0 ) 2024-07-29 |
Last Dividend | ¥5.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 8.48 |
ATR14 | ¥3.11 (0.00%) |
Volum Korrelasjon
CMIC HOLDINGS Co., Ltd. Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
CMIC HOLDINGS Co., Ltd. Korrelasjon - Valuta/Råvare
CMIC HOLDINGS Co., Ltd. Økonomi
Annual | 2023 |
Omsetning: | ¥104.70B |
Bruttogevinst: | ¥24.70B (23.59 %) |
EPS: | ¥416.23 |
FY | 2023 |
Omsetning: | ¥104.70B |
Bruttogevinst: | ¥24.70B (23.59 %) |
EPS: | ¥416.23 |
FY | 2022 |
Omsetning: | ¥108.46B |
Bruttogevinst: | ¥26.26B (24.21 %) |
EPS: | ¥469.41 |
FY | 2021 |
Omsetning: | ¥85.79B |
Bruttogevinst: | ¥17.73B (20.66 %) |
EPS: | ¥111.87 |
Financial Reports:
No articles found.
CMIC HOLDINGS Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥10.00 (N/A) |
¥0 (N/A) |
¥5.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥2.50 | 2004-09-27 |
Last Dividend | ¥5.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 39 | -- |
Total Paid Out | ¥394.60 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.76 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 3.88 | |
Div. Directional Score | 7.89 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
7976.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
7212.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
6458.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5464.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4461.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3641.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2897.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
1716.T | Ex Dividend Knight | 2024-06-27 | Annually | 0 | 0.00% | |
9308.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8285.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0572 | 1.500 | 8.86 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0785 | 1.200 | 7.38 | 8.86 | [0 - 0.3] |
returnOnEquityTTM | 0.147 | 1.500 | 9.48 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.01 | 0.800 | 4.97 | 3.97 | [1 - 3] |
quickRatioTTM | 1.503 | 0.800 | 5.87 | 4.69 | [0.8 - 2.5] |
cashRatioTTM | 0.617 | 1.500 | 7.69 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0385 | -1.500 | 9.36 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 57.84 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 453.56 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 453.56 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0737 | -1.500 | 9.71 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.223 | 1.000 | 9.61 | 9.61 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0745 | 1.000 | -0.509 | -0.509 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.93 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 1.372 | 0.800 | 4.19 | 3.35 | [0.5 - 2] |
Total Score | 11.90 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.38 | 1.000 | 9.25 | 0 | [1 - 100] |
returnOnEquityTTM | 0.147 | 2.50 | 9.67 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 453.56 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.702 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 453.56 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.740 | 1.500 | -8.27 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0823 | 1.000 | -0.443 | 0 | [0.1 - 0.5] |
Total Score | 3.88 |
CMIC HOLDINGS Co., Ltd.
CMIC HOLDINGS Co., Ltd. provides various services for the pharmaceutical industry in Japan. The company operates in five segments: Contract Research Organization, Contract Development and Manufacturing Organization, Contract Sales Organization, Healthcare, and Innovative Pharma Model. It offers clinical trial services, including clinical operations and trials, data management, clinical caretaker, medical writing, patient recruitment, pharmacovigilance, project management, audit and quality assurance, and statistical analysis; and clinical site network, CMC, drug development, health economics and outcome research, market entry/out-licensing, medical devices and in vitro diagnostic consulting, medical writing, national health insurance pricing, and product life cycle management consulting services. The company also provides development and manufacturing services, including commercial supply, contract development and manufacturing, investigational product manufacturing, packaging and labeling, release and stability tests, technology transfer, as well as formulation, process, and analytical development services; and laboratory services, such as bioanalysis and GLP analysis, biomarkers, CMC and GMP analysis, large molecule, oligonucleotides, small molecule, and toxicity, as well as safety pharmacology, in vitro and in vivo, and non-clinical studies. In addition, it offers patient and healthcare services, such as drug adherence support program, harmo, Helc+, prescription drug database, and selcheck services; and post-marketing surveillance, self-inspection, regulatory affairs consulting, regulatory submissions and correspondence, sales and marketing, clinical research coordinating, clinical site administration, and site management services. CMIC HOLDINGS Co., Ltd. has a partnership with Science 37, Inc. to decentralize clinical trials and enhance the development of treatments. The company was incorporated in 1985 and is headquartered in Tokyo, Japan.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.